Well it tells me ( according to Granowitz ) that the study population is not "as sick " as many surmised....at least not now Earlier studies with diabetics had shown placebo rates of around 5.8% So either there are less diabetics in R-IT then thought or treatment has improved for the diabetics in the trial ( my view )
Either way ...as Mrmain pointed out ...company earlier guided that placebo rate could be as low as 5.2%...but now Granowitz says trial was designed around a population with an event rate of approximately 5% --------------------------------- The population being studied in REDUCE-IT with well-controlled bad cholesterol, but other CV risk factors and without potential benefits of Vascepa was assumed in the design of the study to incur major adverse cardiovascular events at a rate approximately 5% per year.
--------------------------------- Alwayswatching ...didn't see your guess in RRR in Gabors contest . Care to throw out a # for the record ? Kiwi
Market Data 
Markets 
AI
